SEHK:2696Biotechs
Shanghai Henlius Biotech (SEHK:2696) Margin Compression Tests Bullish Growth Narratives
Shanghai Henlius Biotech (SEHK:2696) has reported its FY 2025 results with first half revenue of C¥2.8b and basic EPS of C¥0.72, set against trailing 12 month revenue of C¥6.7b and EPS of C¥1.52 that give investors a fuller picture of its recent performance. Over recent periods, revenue has moved from C¥2.75b in 1H 2024 to C¥2.98b in 2H 2024 and C¥2.82b in 1H 2025, while EPS has tracked from C¥0.71 to C¥0.80 and then C¥0.72, leaving the current update framed by solid net income in the...